Zobrazeno 1 - 10
of 159
pro vyhledávání: '"Frédéric Hollande"'
Autor:
Laura J. Jenkins, Ian Y. Luk, Fiona Chionh, Tao Tan, Kristen Needham, Jamieson Ayton, Camilla M. Reehorst, Natalia Vukelic, Oliver M. Sieber, Dmitri Mouradov, Peter Gibbs, David S. Williams, Niall C. Tebbutt, Jayesh Desai, Frédéric Hollande, Amardeep S. Dhillon, Erinna F. Lee, Delphine Merino, W. Douglas Fairlie, John M. Mariadason
Publikováno v:
Cell Death and Disease, Vol 15, Iss 3, Pp 1-9 (2024)
Abstract Metastatic BRAF V600E colorectal cancer (CRC) carries an extremely poor prognosis and is in urgent need of effective new treatments. While the BRAFV600E inhibitor encorafenib in combination with the EGFR inhibitor cetuximab (Enc+Cet) was rec
Externí odkaz:
https://doaj.org/article/6e4f88d9b616433e88bdbae69ee002cc
Publikováno v:
Frontiers in Cell and Developmental Biology, Vol 11 (2023)
Cancer cell heterogeneity is a key contributor to therapeutic failure and post-treatment recurrence. Targeting cell subpopulations responsible for chemoresistance and recurrence seems to be an attractive approach to improve treatment outcome in cance
Externí odkaz:
https://doaj.org/article/f6a3b50e04f84654b806d0948ec07310
Autor:
Julia Dubowitz, Alexandra I Ziegler, Richard Beare, Fabian Jost-Brinkmann, Adam K Walker, Ryan D Gillis, Aeson Chang, Ni-Chun Chung, Olga A Martin, Frédéric Hollande, Bernhard Riedel, Erica K Sloan
Publikováno v:
PLoS ONE, Vol 18, Iss 11, p e0293905 (2023)
BackgroundSurgery is essential for curative treatment of solid tumors. Evidence from recent retrospective clinical analyses suggests that use of propofol-based total intravenous anesthesia during cancer resection surgery is associated with improved o
Externí odkaz:
https://doaj.org/article/3847f45936474b739852fce36cd2452a
Publikováno v:
Frontiers in Immunology, Vol 13 (2023)
The protective role of Natural Killer (NK) cell tumour immunosurveillance has long been recognised in colorectal cancer (CRC). However, as most patients show limited intra-tumoral NK cell infiltration, improving our ability to identify those with hig
Externí odkaz:
https://doaj.org/article/dcbd1cafc74045d0a6e02eb99f80274f
Autor:
Roxane M. Pommier, Amélien Sanlaville, Laurie Tonon, Janice Kielbassa, Emilie Thomas, Anthony Ferrari, Anne-Sophie Sertier, Frédéric Hollande, Pierre Martinez, Agnès Tissier, Anne-Pierre Morel, Maria Ouzounova, Alain Puisieux
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-12 (2020)
Claudin-low tumors are a rare aggressive subtype of breast cancers. In this study, the authors use a multiomics approach to demonstrate that these tumors are heterogeneous and comprise three main subgroups that emerge from different evolutionary proc
Externí odkaz:
https://doaj.org/article/fd71c30afd354a149f4036cea3f453ff
Publikováno v:
EMBO Molecular Medicine, Vol 13, Iss 11, Pp n/a-n/a (2021)
Abstract Dependence receptors are known to promote survival and positive signaling such as proliferation, migration, and differentiation when activated, but to actively trigger apoptosis when unbound to their ligand. Their abnormal regulation was sho
Externí odkaz:
https://doaj.org/article/0c4f0d08899a4d80b0e26d0f7659852a
Autor:
Jean Berthelet, Momeneh Foroutan, Dharmesh D. Bhuva, Holly J. Whitfield, Farrah El-Saafin, Joseph Cursons, Antonin Serrano, Michal Merdas, Elgene Lim, Emmanuelle Charafe-Jauffret, Christophe Ginestier, Matthias Ernst, Frédéric Hollande, Robin L. Anderson, Bhupinder Pal, Belinda Yeo, Melissa J. Davis, Delphine Merino
Publikováno v:
Cancers, Vol 14, Iss 10, p 2404 (2022)
The development of therapies that target specific disease subtypes has dramatically improved outcomes for patients with breast cancer. However, survival gains have not been uniform across patients, even within a given molecular subtype. Large collect
Externí odkaz:
https://doaj.org/article/03fba90710854702b0036094e42aa149
Autor:
Sophia Ceder, Sofi E Eriksson, Emarndeena H Cheteh, Swati Dawar, Mariana Corrales Benitez, Vladimir J N Bykov, Kenji M Fujihara, Mélodie Grandin, Xiaodun Li, Susanne Ramm, Corina Behrenbruch, Kaylene J Simpson, Frédéric Hollande, Lars Abrahmsen, Nicholas J Clemons, Klas G Wiman
Publikováno v:
EMBO Molecular Medicine, Vol 13, Iss 2, Pp n/a-n/a (2021)
Abstract The tumor suppressor gene TP53 is the most frequently mutated gene in cancer. The compound APR‐246 (PRIMA‐1Met/Eprenetapopt) is converted to methylene quinuclidinone (MQ) that targets mutant p53 protein and perturbs cellular antioxidant
Externí odkaz:
https://doaj.org/article/ad163b956af24ac198adeee8afcb4f6a
Autor:
Carolyn Shembrey, Jai Smith, Mélodie Grandin, Nathalia Williams, Hyun-Jung Cho, Christina Mølck, Corina Behrenbruch, Benjamin NJ. Thomson, Alexander G. Heriot, Delphine Merino, Frédéric Hollande
Publikováno v:
Cancers, Vol 14, Iss 3, p 581 (2022)
Geno- and phenotypic heterogeneity amongst cancer cell subpopulations are established drivers of treatment resistance and tumour recurrence. However, due to the technical difficulty associated with studying such intra-tumoural heterogeneity, this phe
Externí odkaz:
https://doaj.org/article/271ee8fcc235466b838aca3688212920
Autor:
Guillaume Belthier, Zeinab Homayed, Fanny Grillet, Christophe Duperray, Julie Vendrell, Ilona Krol, Sophie Bravo, Jean-Christophe Boyer, Olivia Villeronce, Jihane Vitre-Boubaker, Diana Heaug-Wane, Françoise Macari-Fine, Jai Smith, Matthieu Merlot, Gérald Lossaint, Thibault Mazard, Fabienne Portales, Jérôme Solassol, Marc Ychou, Nicola Aceto, Emilie Mamessier, François Bertucci, Jean Marc Pascussi, Emmanuelle Samalin, Frédéric Hollande, Julie Pannequin
Publikováno v:
Cancers, Vol 13, Iss 19, p 4966 (2021)
Circulating tumor cells (CTCs) are promising diagnostic and prognostic tools for clinical use. In several cancers, including colorectal and breast, the CTC load has been associated with a therapeutic response as well as progression-free and overall s
Externí odkaz:
https://doaj.org/article/2879e232f7414747a84f5af15b30ff47